Omri Amirav-Drory Bio: The Synthetic Biology Pioneer & NFX Partner, Age, Height, Career, Net Worth, Family & Recent Ventures

Omri Amirav-Drory is a visionary Israeli-American scientist, entrepreneur, and venture capitalist who has become one of the most influential figures in the intersection of biology and technology. As a General Partner at NFX and the founder of Genome Compiler, he is widely recognized as a pioneer of the “TechBio” movement, which treats biology as a programmable platform rather than a series of slow, artisanal experiments. By bridging the gap between computer science and molecular biology, Amirav-Drory has spent the last two decades accelerating the pace of drug discovery, sustainable materials, and genetic engineering.

Quick Facts

Early Life & Education

Childhood

Omri Amirav-Drory was born and raised in Israel during a period of significant technological growth in the region. Growing up in an environment that valued both rigorous scientific inquiry and the “chutzpah” required for entrepreneurship, he showed an early interest in how the natural world functioned at a molecular level. His parents encouraged a multidisciplinary education, which eventually led him to see biology not just as a medical field, but as an engineering discipline.

School Years

During his formative years in Israel, Omri excelled in the sciences, particularly chemistry and physics. He was known among his peers for his ability to simplify complex systems, a trait that would later define his career in synthetic biology. After completing his mandatory military service—a standard but often transformative experience for Israeli tech leaders—he focused his intellectual energy on the nascent field of biochemistry.

University & Training

Amirav-Drory’s academic pedigree is world-class. He attended Tel Aviv University, where he earned his Ph.D. in Biochemistry. His research focused on the fundamental mechanisms of life, specifically how proteins interact within cells.

Following his doctorate, he moved to the United States for a prestigious postdoctoral fellowship at Stanford University. Working in the lab of Nobel Laureate Brian Kobilka, Omri specialized in structural biology and G-protein-coupled receptors (GPCRs). It was at Stanford that he realized the tools available to biologists were decades behind the tools available to software engineers. This realization became the catalyst for his transition from the laboratory bench to the CEO’s office.

Career Journey

The career of Omri Amirav-Drory is a roadmap of the “TechBio” evolution. He has successfully navigated the roles of academic researcher, startup founder, corporate executive, and top-tier investor.

The Founding of Genome Compiler (2011–2016)

In 2011, Omri founded Genome Compiler Corp, a company that would change the way geneticists worked. Before Genome Compiler, designing a DNA sequence was a tedious, manual process. Omri’s vision was to create “AutoCAD for Biology”—a software platform that allowed scientists to design, simulate, and order synthetic DNA through an intuitive digital interface.

The company was a central pillar of the early synthetic biology community. It democratized genetic design, making it accessible to smaller labs and independent researchers. Under his leadership as CEO, the company grew rapidly and caught the attention of the industry’s biggest players.

Acquisition by Twist Bioscience (2016–2018)

In 2016, Genome Compiler was acquired by Twist Bioscience, a public company that specializes in high-throughput DNA synthesis. Post-acquisition, Omri joined Twist as the Head of Corporate Development. During his tenure, he played a critical role in integrating the software capabilities of Genome Compiler into Twist’s manufacturing pipeline, helping the company scale into a global powerhouse in the synthetic DNA market.

Transition to NFX and the TechBio Manifesto

In 2018, Omri shifted his focus to venture capital, joining NFX as a General Partner. NFX is a seed-stage venture firm known for its focus on network effects. Omri spearheaded the firm’s dedicated TechBio fund, arguing that the biggest companies of the next decade will not be pure “Bio” or pure “Tech” companies, but a hybrid of both.

He is credited with co-authoring the “TechBio Manifesto,” which outlines a future where biology is engineered using AI, robotics, and cloud computing. His investment philosophy centers on companies that treat biology as an information science.

Career Stats & Key Portfolio Companies

Net Worth & Earnings

As of 2026, Omri Amirav-Drory’s estimated net worth is between $150 million and $200 million. His wealth is derived from several high-value sources:

1. Equity in Twist Bioscience: The acquisition of Genome Compiler was largely settled in equity. As Twist Bioscience (TWST) grew into a multi-billion dollar entity, Omri’s early holdings appreciated significantly.
2. General Partner Carry at NFX: As a GP at one of the most successful seed-stage firms in Silicon Valley, Omri earns a significant percentage of the profits (carried interest) from the funds he manages.
3. Angel Investments: Before joining NFX, Omri was an active angel investor in several “unicorns” within the synthetic biology space.
4. Board Roles: He holds several compensated board positions at private and public biotechnology companies.

Omri is also a proponent of “Long-termism” in investing, often putting his capital into “hard science” projects that may take a decade to mature but offer massive societal and financial returns.

Personal Life

Family Background

Omri maintains a relatively private personal life, keeping his family away from the limelight of the tech press. He is married and is a father to two children. He frequently mentions in interviews that his desire to solve climate change and cure diseases through synthetic biology is driven by a responsibility to his children’s future.

Hobbies & Interests

When he is not analyzing pitch decks or sequencing data, Omri is known to be an avid outdoorsman. He enjoys hiking and exploring the natural beauty of the California coast, which often serves as inspiration for his work in biomimicry. He is also a deeply philosophical reader, citing works on the history of science and the ethics of genetic engineering as his primary interests.

Awards & Achievements

• SynBioBeta Pioneer Award (2021): Recognized for his contributions to the synthetic biology ecosystem.
• Top 40 Under 40 in Biotech: Previously named by various industry publications as a leader to watch.
• Stanford Postdoctoral Excellence: Acknowledged for his high-impact research in crystallography alongside Brian Kobilka.
• TechBio Visionary List (2024): Ranked as one of the top 10 most influential investors in the intersection of AI and Biology.

Physical Statistics

• Height: 5 feet 10 inches (178 cm).
• Weight: Approximately 165 lbs (75 kg).
• Physique: Lean and athletic, maintained through a consistent routine of swimming and hiking.
• Notable Attributes: Known for his energetic speaking style and sharp, analytical gaze during panel discussions.

Quotes

“Biology is the most advanced technology on Earth. We just didn’t write the code; we inherited it. Our job now is to learn how to read and rewrite it for the benefit of humanity.” — NFX TechBio Summit, 2022

“The difference between Biotech and TechBio is the difference between guessing and engineering.” — Interview with TechCrunch, 2023

Interesting Facts

• Nobel Connection: He did his postdoctoral work with Brian Kobilka, who won the Nobel Prize in Chemistry in 2012.
• First Mover: He was one of the first people to advocate for the “Bio-Economy” long before it became a standard government term.
• Software Roots: Despite being a PhD in Biochemistry, he is proficient in several programming languages and views DNA as “software for the physical world.”
• Global Citizen: He splits his time between the US and Israel, acting as a bridge for Israeli startups looking to enter the Silicon Valley market.
• Sustainability Focus: He is a major investor in “cellular agriculture,” believing that we will soon grow meat and leather in labs rather than on farms.
• CRISPR Advocate: He was an early supporter of CRISPR technology and has funded several companies that use the gene-editing tool for non-medical applications.
• Space Biology: He has expressed interest in how synthetic biology will be required for long-term human survival on Mars.

Did You Know?

• Did you know Omri Amirav-Drory’s first company, Genome Compiler, was often called the “Google Docs for DNA”?
• Did you know he once worked on the molecular structure of the human heart’s receptors?
• Did you know Omri believes that within 20 years, we will “print” medicines in our own homes using small desktop DNA synthesisers?
• Did you know he is a frequent guest lecturer at Stanford and Singularity University?

Social Media

• LinkedIn: Omri Amirav-Drory
• X (Twitter): @OmriAD
• NFX Profile: nfx.com/team/omri-amirav-drory

Frequently Asked Questions

Q1: What is Omri Amirav-Drory’s main contribution to science?
Omri is best known for creating software tools that allow scientists to design synthetic DNA sequences digitally. This moved the field of biology from a manual “trial and error” process to a more predictable engineering discipline.

Q2: What is “TechBio”?
A term popularized by Omri and NFX, TechBio refers to companies that use modern technology (AI, automation, software) as their core foundation to solve biological problems, as opposed to traditional biotech companies that may only use tech as a secondary tool.

Q3: Is Omri Amirav-Drory still involved with Twist Bioscience?
While he transitioned into venture capital with NFX, he remains a significant figure in the Twist ecosystem and is often associated with the company’s early growth and strategic software acquisitions.

Q4: Where does Omri Amirav-Drory live?
He currently resides in the San Francisco Bay Area, California, which allows him to be at the center of the Silicon Valley tech and biology scene.

CONCLUSION

Omri Amirav-Drory has successfully redefined what it means to be a biologist in the 21st century. By treating the genetic code with the same rigor that a software engineer treats C++ or Python, he has unlocked new possibilities in medicine, agriculture, and environmental sustainability. As a General Partner at NFX, his influence continues to grow as he funds the next generation of founders who believe that biology is the ultimate manufacturing platform. His legacy will likely be seen in the transition from a world that extracts resources from nature to a world that designs and grows them.

Sources: NFX Official Bio, Twist Bioscience Investor Relations, Stanford University Department of Molecular and Cellular Physiology, Crunchbase, Forbes Technology Council.